Abstracts

PSY12 
ECONOMIC EVALUATION OF RECOMBINANT FACTOR VIII PRODUCTS IN TREATMENT OF HAEMOPHILIA A IN KOREA

Kim JY*, Lee JH*, Heo JH*, Lee BK.
Sook Myung Women’s University, Seoul, South Korea; *Sook Myung Women’s University, Seoul, South Korea.

OBJECTIVES: Haemophilia A is a hereditary genetic disorder with a relatively high burden of disease from the perspective of both society and the individual patient. Kogenate FS is a second-generation full-length recombinant factor VIII (FVIII), produced with the addition of human albumin during formulation. It showed a significantly lower incidence of inhibitors compared with other recombinant factor VIII products, which has an impact on economic evaluation because the haemophilia patients with inhibitors have to be treated with a significantly higher dosage or expensive bypassing agents. The main objective of this study is to conduct economic evaluation of Kogenate FS compared with Recombinate in haemophilia A patients in Korea. METHODS: A cost minimization analysis was performed under the assumption that Kogenate FS and Recombinate were clinically equivalent for treating bleeding episodes. A decision analysis was developed to estimate the lifetime costs by reflecting each different treatment strategies for haemophilia A patients with inhibitors or not. If patients had inhibitors, it was ramified according to the inhibitor titres into one of three pathways: <8IU, 8~100IU, >100IU. The analysis was conducted based on the societal perspective, and costs were discounted at 3% annually. Sensitivity analyses were performed on crucial parameters. RESULTS: Incidence of inhibitor for Kogenate FS and Recombinate were 8.113% and 16.9% respectively. Using the base case analysis, the expected cost for Kogenate FS was US$1,799,133 compared with $2,182,332 for Recombinate. So, Kogenate FS is $403,199 lower than Recombinate during lifetime. The differences were mainly due to the higher inhibitor treatment costs. One-way sensitivity analysis revealed stable across included parameters. CONCLUSIONS: This cost minimization study identified that treatment of Kogenate FS appears to save costs compared with treatment of Recombinate. By initiating and continuing Kogenate FS treatment, the economic cost associated with Haemophilia A can be reduced under Korean healthcare system.

PSY23 
ECONOMIC EVALUATION OF DARBEPOETIN ALFA AND EPOETIN IN HEMODIALYSIS PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE

Vakharova P*, Lenishcheva P*, Aleksisceva M, Nekrasova N.
Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia; *Russian Society For Pharmacoeconomics and Outcomes Research, Moscow, Russia; Moscow Medical Academy named after I.M.Sechenov, Moscow, Russia.

OBJECTIVES: To perform economical evaluation of darbeopotin alfa vs. epoetin alfa in hemodialysis patients with anemia and chronic kidney disease. METHODS: The modeled study was performed. Proportion of patients receiving alternative eritropoiesis-stimulating proteins (ESP) dosing regimen, efficacy and safety of drugs were extracted from multicenter randomized study made by Nilsson et al (American Journal of Kidney Diseases 2002, 1:110-8). Cost of treatment with ESPs for 28 weeks and cost-minimization ratio (CMR) were calculated from the Russian reimbursement system point of view. RESULTS: According to selected study, the efficacy and safety profile of darbeopotin alfa was similar to that of epoetin alfa. Mean dose decrease from 6.5±4 µg/kg to 5.1±4 µg/kg was observed in darbeopotin alfa group, while mean dose increase from 12,706 to 33,639 was registered in epoetin alfa group during 28 weeks. The costs of used medications were the same for darbeopotin alfa and epoetin alfa (RUB230,548.1 vs. RUB 229,427.19 (USD$2,792 vs. USD$2,69.56). The cost of medical manipulations were less for darbeopotin alfa due to its reduced dosing fre- quency (RUB228.48 vs. RUB6854.8 (USD$2.4 vs. USD217.2) accordingly). Cost minimization analysis showed that cost of treatment with darbeopotin alfa is less than epoetin alfa (CER = RUB338.7 ($US70.3)). Sensitivity analysis was made on the basis of model, constructed with data extracted from other study (Molina et al, Nephrology 2004; 6). It confirmed the results of present work. CONCLUSIONS: According to the model darbeopotin alfa seems to be as effective and safe as epoetin alfa, but it takes fewer costs for treatment of anemia in hemodialysis patients with chronic kidney disease due to low dosing frequency and dose saving effect.

PSY24 
THE IMPACT OF OBESITY ON MEDICAL EXPENSE AND HEALTH RELATED QUALITY OF LIFE

Kawagori AA, Nichol MB
Paciencia of Southern California, Los Angeles, CA, USA.

OBJECTIVES: To quantify the effect of obesity on the total direct medical expenditure and health related quality of life in the population of the United States. METHODS: Data from the MIEPs Household Component (2006), a nationally representative survey of 22,000 non-institutionalized population, was used. Analysis accounted for the survey’s clusters, strata and sampling weights. Obesity was defined as body mass index ≥30. Direct medical expenditure attributable to obesity was esti- mated under diverse econometric models to assess sensitivity to zero-mass, non-nega- tive costs and skewed distribution. Models compared were Ordinary Least Squares (OLS) on raw and log-transformed expenditures (homoskedastic and heteroskedastic re-transformations), and generalized linear models (GLM) with log-link and Gamma/ Poisson families, including 2-part variants of these 5 models. Box-Cox test and Modi- fied Park’s test determined the link and family in the GLM models. LINK, RESET, Hosmer-Lemeshow and Pearson’s correlation test determined model fit, while Copas test was employed for over-fitting and cross validation. Incremental expenditure from the method of recycled predictions summed up over population with obesity gave the total expenditure. Impact of obesity on HF21 mental and physical health component was assessed by OLS. Covariates included age, gender, race, ethnicity, income, geographic-location, and comorbidity. RESULTS: The 2-part model of OLS on raw expenditure was the only model to pass all the specification and cross-validation tests. Based on this model, annual incremental expenditure of obesity was $118,850 (93% $3,390.7 to $119,300). Total direct expenditure of obesity was $72 billion (95% CI $68,2 to $75.8 billion), nearly 3-fold increase compared to 1998 estimates. SF21 physical component score was lower by 1.7 (p < 0.001) while the mental component score was lower by 1.2 (p < 0.001) for those with obesity. These decrements are similar to that observed for diabetes or hypertension. CONCLUSIONS: Obesity exerts an enormous economic and humanistic burden on the U.S. civilian non-institutionalized population.

PSY25 
MEDICAL TREATMENT COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH ASTHMA AMONG U.S. ADULTS

Yu J, Yang JC, Brevik JH
Rutgers University, Piscataway, NJ, USA; Catholic University, Seoul, South Korea; *Health Insurance Review & Assessment Service, Seoul, South Korea; *Korea National Health Insurance Corporation, Mapo-gu, Seoul, South Korea

OBJECTIVES: To estimate the potential attributable cost of asthma with obesity and the annual medical costs attributable to obesity. METHODS: The cross-sectional analysis was conducted from adults aged 18-74 who participated in the 2003-2006 Medical Expenditure Panel Survey. Total of 6670 asthma patients were identified based on the self reported diagnosis or ICD-9-CM code of 493 after excluding patients with pregnancy, malignancy, kidney dialysis, immunodeficiency, or body mass-index (BMI) ≥35. These patients were classified as normal (BMI:18.5-25) or obese (BMI≥30). Total medical costs included office based physician/outpatient visits, emergency room visit, or hospitalization except dental problems and injuries. Costs related to respiratory system diseases were associated with ICD-9-CM codes 490-516. The medical cost attributable to obesity was the difference between the observed cost and the predicted cost which was calculated using the parameters estimated from obese patients. The parameters for obese patients were estimated using a general linearized model with a log link function and a gamma distribution after adjusting for demographic, social-economic, and co-morbidity variables. All costs were converted to 2006 U.S. dollars using price indices. Data were analyzed using SAS/STATA. RESULTS: The age-adjusted prevalence of asthma in total population was 8.2% and that of asthma with obesity was 2.8% respectively. The average total medical treatment costs in obese asthma patients were $5090 (95% CI $4639-$5540), significantly higher than normal weight patients ($2,825; 95% CI $2291-$3359 p < 0.001). After adjustments, the total medical costs attributable to obesity per patient were $3,960 (95% CI $3,691-$4,228). Of that cost, $154 was attributable to respiratory system diseases (95% CI $48-$259) with the biggest increment in patients aged 65-74 old. CONCLUSIONS: Obesity is prevalent in general population as well as asthma patients. The average medical cost attributable to obesity was significantly higher than normal weight asthma patients. Effective public programs aiming at educating the importance of controlling weight are strongly recommended to diminish the economic burden of obesity.

PSY26 
COST OF OPIOID USE IN A COMMERCIAILY INSURED POPULATION OF FIBROMYALGIA PATIENTS

Yan J, Blum 3, Beard FM
Forest Research Institute, Jersey City, NJ, USA.

OBJECTIVES: Although opioids have not demonstrated efficacy in treating fibromy- algia (FM) and pose a risk for addiction, they are commonly used to treat FM patients. This study assesses the mean annual per patient cost of FM-related opioid use in commercially insured FM patients. METHODS: Using the ThomsonMedstat Mar- ketScan Commercial Claims Database, we identified all patients age 18+ years with consistent health plan eligibility in 2006 and 21 inpatient or 22 outpatient paid medical claims in calendar year 2006 with ICD-9-CM diagnosis code 729.1 (“FM patients”). RX medications designated as possibly related to FM treatment (“FM-